{"id":60827,"date":"2026-02-27T11:03:27","date_gmt":"2026-02-27T11:03:27","guid":{"rendered":"https:\/\/www.globalresearch.co.kr\/insight\/novel-t-cell-immunotherapy-market-mordor\/"},"modified":"2026-10-02T06:01:16","modified_gmt":"2026-10-01T21:01:16","slug":"novel-t-cell-immunotherapy-market-mordor","status":"publish","type":"post","link":"https:\/\/www.globalresearch.co.kr\/insight\/novel-t-cell-immunotherapy-market-mordor\/","title":{"rendered":"\uc138\uacc4\uc758 \uc2e0\uaddc T\uc138\ud3ec \uba74\uc5ed\uce58\ub8cc\uc81c \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc810\uc720\uc728 \ubd84\uc11d &#8211; \uc131\uc7a5 \ub3d9\ud5a5 \ubc0f \uc804\ub9dd (2025-2030\ub144)"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/www.globalresearch.co.kr\/insight\/wp-content\/uploads\/2026\/02\/novel-t-cell-immunotherapy-market-1757574258730-major-players.webp\" alt=\"Chart\" class=\"aligncenter size-full\" \/><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.globalresearch.co.kr\/insight\/wp-content\/uploads\/2026\/02\/novel-t-cell-immunotherapy-market-size-image-1757574104821.webp\" alt=\"Chart\" class=\"aligncenter size-full\" \/><\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-0\">1. \uc11c\ub860<\/p>\n<ul>\n<li class=\"toc-level-2\">1.1 \uc5f0\uad6c \uac00\uc815 \ubc0f \uc2dc\uc7a5 \uc815\uc758<\/li>\n<li class=\"toc-level-2\">1.2 \uc5f0\uad6c \ubc94\uc704<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-1\">2. \uc5f0\uad6c \ubc29\ubc95\ub860<\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-2\">3. \uc694\uc57d<\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-3\">4. \uc2dc\uc7a5 \ud658\uacbd<\/p>\n<ul>\n<li class=\"toc-level-2\">4.1 \uc2dc\uc7a5 \uac1c\uc694<\/li>\n<li class=\"toc-level-2\">4.2 \uc2dc\uc7a5 \ub3d9\uc778\n<ul>\n<li class=\"toc-level-3\">4.2.1 \uc2e0\uc18d \uc2b9\uc778 \ubc0f RMAT\/PRIME \uc9c0\uc815\uc744 \ud1b5\ud55c \uaddc\uc81c \uc9c0\uc6d0<\/li>\n<li class=\"toc-level-3\">4.2.2 \uc885\uc591\ud559 \ubc0f \uc790\uac00\uba74\uc5ed \ubd84\uc57c\uc758 \ud6c4\uae30 \uc784\uc0c1 \ud30c\uc774\ud504\ub77c\uc778\uc758 \uae09\uc18d\ud55c \ud655\uc7a5<\/li>\n<li class=\"toc-level-3\">4.2.3 \uc720\uc804\uc790 \ud3b8\uc9d1 \ubc0f \uc138\ud3ec \uc81c\uc870 \ud50c\ub7ab\ud3fc\uc758 \ud601\uc2e0\uc73c\ub85c \ud6a8\ub2a5 \ubc0f \uc0dd\uc0b0\ub7c9 \uc99d\ub300<\/li>\n<li class=\"toc-level-3\">4.2.4 \uc0c1\uc5c5\ud654\ub97c \uc704\ud55c \uc804\ub7b5\uc801 \uc790\ubcf8 \uc720\uc785 \ubc0f \uae00\ub85c\ubc8c \ud30c\ud2b8\ub108\uc2ed \ud655\ub300<\/li>\n<li class=\"toc-level-3\">4.2.5 \uce58\ub8cc \ubaa9\uc801\uc758 \uc77c\ud68c\uc131 \uce58\ub8cc\uc81c\uc5d0 \ub300\ud55c \uc758\ub8cc \uc2dc\uc2a4\ud15c\uc758 \uc9c0\ubd88 \uc758\uc0ac \uc99d\uac00<\/li>\n<li class=\"toc-level-3\">4.2.6 \uacf5\uc778 \uce58\ub8cc \uc13c\ud130\uc758 \uc9c0\ub9ac\uc801 \ud655\uc7a5\uc73c\ub85c \ud658\uc790 \uc811\uadfc\uc131 \ud5a5\uc0c1<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">4.3 \uc2dc\uc7a5 \uc81c\uc57d\n<ul>\n<li class=\"toc-level-3\">4.3.1 \ucd08\uace0\uac00 \uc0c1\ud488 \ube44\uc6a9 \ubc0f \ubd88\ud655\uc2e4\ud55c \uc7a5\uae30 \uc0c1\ud658 \ud504\ub808\uc784\uc6cc\ud06c<\/li>\n<li class=\"toc-level-3\">4.3.2 \ubcf5\uc7a1\ud558\uace0 \uc790\uc6d0 \uc9d1\uc57d\uc801\uc778 \uc81c\uc870 \ubc0f \ubb3c\ub958\ub85c \uc778\ud55c \ud655\uc7a5\uc131 \uc81c\ud55c<\/li>\n<li class=\"toc-level-3\">4.3.3 \uc0ac\uc774\ud1a0\uce74\uc778 \ud3ed\ud48d \ubc0f \uc2e0\uacbd\ub3c5\uc131\uc744 \ud3ec\ud568\ud55c \uc548\uc804 \uad00\ub9ac \ubb38\uc81c<\/li>\n<li class=\"toc-level-3\">4.3.4 \uc2e0\ud765 \uc2dc\uc7a5\uc758 \uaddc\uc81c \uc774\uc9c8\uc131 \ubc0f \ubcd1\uc6d0 \uc778\ud504\ub77c \uaca9\ucc28<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">4.4 \uacf5\uae09\ub9dd \ubd84\uc11d<\/li>\n<li class=\"toc-level-2\">4.5 \uaddc\uc81c \ud658\uacbd<\/li>\n<li class=\"toc-level-2\">4.6 \uae30\uc220 \uc804\ub9dd<\/li>\n<li class=\"toc-level-2\">4.7 \ud3ec\ud130\uc758 5\uac00\uc9c0 \uacbd\uc7c1\uc694\uc778 \ubd84\uc11d\n<ul>\n<li class=\"toc-level-3\">4.7.1 \uacf5\uae09\uc5c5\uccb4\uc758 \uad50\uc12d\ub825<\/li>\n<li class=\"toc-level-3\">4.7.2 \uad6c\ub9e4\uc790\uc758 \uad50\uc12d\ub825<\/li>\n<li class=\"toc-level-3\">4.7.3 \uc2e0\uaddc \uc9c4\uc785\uc790\uc758 \uc704\ud611<\/li>\n<li class=\"toc-level-3\">4.7.4 \ub300\uccb4\uc7ac\uc758 \uc704\ud611<\/li>\n<li class=\"toc-level-3\">4.7.5 \uacbd\uc7c1 \uac15\ub3c4<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-4\">5. \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc131\uc7a5 \uc608\uce21 (\uac00\uce58, USD)<\/p>\n<ul>\n<li class=\"toc-level-2\">5.1 \uce58\ub8cc \uc720\ud615\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.1.1 CAR-T<\/li>\n<li class=\"toc-level-3\">5.1.2 TCR-T<\/li>\n<li class=\"toc-level-3\">5.1.3 \uc885\uc591 \uce68\uc724 \ub9bc\ud504\uad6c (TIL)<\/li>\n<li class=\"toc-level-3\">5.1.4 T\uc138\ud3ec \uc778\uac8c\uc774\uc800\/BiTE<\/li>\n<li class=\"toc-level-3\">5.1.5 \uae30\ud0c0 \uc0c8\ub85c\uc6b4 \uc591\uc2dd<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.2 \uc138\ud3ec \uacf5\uae09\uc6d0\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.2.1 \uc790\uac00<\/li>\n<li class=\"toc-level-3\">5.2.2 \ub3d9\uc885<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.3 \uc801\uc751\uc99d\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.3.1 \ud608\uc561\uc554<\/li>\n<li class=\"toc-level-3\">5.3.2 \uace0\ud615\uc554<\/li>\n<li class=\"toc-level-3\">5.3.3 \uc790\uac00\uba74\uc5ed \uc9c8\ud658<\/li>\n<li class=\"toc-level-3\">5.3.4 \ubc14\uc774\ub7ec\uc2a4 \uac10\uc5fc<\/li>\n<li class=\"toc-level-3\">5.3.5 \uae30\ud0c0 \uc801\uc751\uc99d<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.4 \uc9c0\uc5ed\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.4.1 \ubd81\ubbf8<\/li>\n<li class=\"toc-level-4\">5.4.1.1 \ubbf8\uad6d<\/li>\n<li class=\"toc-level-4\">5.4.1.2 \uce90\ub098\ub2e4<\/li>\n<li class=\"toc-level-4\">5.4.1.3 \uba55\uc2dc\ucf54<\/li>\n<li class=\"toc-level-3\">5.4.2 \uc720\ub7fd<\/li>\n<li class=\"toc-level-4\">5.4.2.1 \ub3c5\uc77c<\/li>\n<li class=\"toc-level-4\">5.4.2.2 \uc601\uad6d<\/li>\n<li class=\"toc-level-4\">5.4.2.3 \ud504\ub791\uc2a4<\/li>\n<li class=\"toc-level-4\">5.4.2.4 \uc774\ud0c8\ub9ac\uc544<\/li>\n<li class=\"toc-level-4\">5.4.2.5 \uc2a4\ud398\uc778<\/li>\n<li class=\"toc-level-4\">5.4.2.6 \uae30\ud0c0 \uc720\ub7fd<\/li>\n<li class=\"toc-level-3\">5.4.3 \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591<\/li>\n<li class=\"toc-level-4\">5.4.3.1 \uc911\uad6d<\/li>\n<li class=\"toc-level-4\">5.4.3.2 \uc77c\ubcf8<\/li>\n<li class=\"toc-level-4\">5.4.3.3 \uc778\ub3c4<\/li>\n<li class=\"toc-level-4\">5.4.3.4 \ub300\ud55c\ubbfc\uad6d<\/li>\n<li class=\"toc-level-4\">5.4.3.5 \ud638\uc8fc<\/li>\n<li class=\"toc-level-4\">5.4.3.6 \uae30\ud0c0 \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591<\/li>\n<li class=\"toc-level-3\">5.4.4 \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74<\/li>\n<li class=\"toc-level-4\">5.4.4.1 GCC<\/li>\n<li class=\"toc-level-4\">5.4.4.2 \ub0a8\uc544\ud504\ub9ac\uce74<\/li>\n<li class=\"toc-level-4\">5.4.4.3 \uae30\ud0c0 \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74<\/li>\n<li class=\"toc-level-3\">5.4.5 \ub0a8\ubbf8<\/li>\n<li class=\"toc-level-4\">5.4.5.1 \ube0c\ub77c\uc9c8<\/li>\n<li class=\"toc-level-4\">5.4.5.2 \uc544\ub974\ud5e8\ud2f0\ub098<\/li>\n<li class=\"toc-level-4\">5.4.5.3 \uae30\ud0c0 \ub0a8\ubbf8<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-5\">6. \uacbd\uc7c1 \ud658\uacbd<\/p>\n<ul>\n<li class=\"toc-level-2\">6.1 \uc2dc\uc7a5 \uc9d1\uc911\ub3c4<\/li>\n<li class=\"toc-level-2\">6.2 \uc2dc\uc7a5 \uc810\uc720\uc728 \ubd84\uc11d<\/li>\n<li class=\"toc-level-2\">6.3 \uae30\uc5c5 \ud504\ub85c\ud544 {(\uae00\ub85c\ubc8c \uac1c\uc694, \uc2dc\uc7a5 \uac1c\uc694, \ud575\uc2ec \ubd80\ubb38, \uc7ac\ubb34, \uc804\ub7b5 \uc815\ubcf4, \uc2dc\uc7a5 \uc21c\uc704\/\uc810\uc720\uc728, \uc81c\ud488 \ubc0f \uc11c\ube44\uc2a4, \ucd5c\uadfc \uac1c\ubc1c \ud3ec\ud568)}\n<ul>\n<li class=\"toc-level-3\">6.3.1 Novartis AG<\/li>\n<li class=\"toc-level-3\">6.3.2 Gilead Sciences (Kite Pharma)<\/li>\n<li class=\"toc-level-3\">6.3.3 Bristol Myers Squibb<\/li>\n<li class=\"toc-level-3\">6.3.4 Johnson &amp; Johnson (Janssen\/Legend)<\/li>\n<li class=\"toc-level-3\">6.3.5 Adaptimmune Therapeutics<\/li>\n<li class=\"toc-level-3\">6.3.6 Allogene Therapeutics<\/li>\n<li class=\"toc-level-3\">6.3.7 Fate Therapeutics<\/li>\n<li class=\"toc-level-3\">6.3.8 Caribou Biosciences<\/li>\n<li class=\"toc-level-3\">6.3.9 Autolus Therapeutics<\/li>\n<li class=\"toc-level-3\">6.3.10 Legend Biotech<\/li>\n<li class=\"toc-level-3\">6.3.11 TCR2 Therapeutics<\/li>\n<li class=\"toc-level-3\">6.3.12 Immatics N.V.<\/li>\n<li class=\"toc-level-3\">6.3.13 Gracell Biotechnologies<\/li>\n<li class=\"toc-level-3\">6.3.14 Bluebird Bio<\/li>\n<li class=\"toc-level-3\">6.3.15 Celyad Oncology<\/li>\n<li class=\"toc-level-3\">6.3.16 Poseida Therapeutics<\/li>\n<li class=\"toc-level-3\">6.3.17 Nkarta Therapeutics<\/li>\n<li class=\"toc-level-3\">6.3.18 Sorrento Therapeutics<\/li>\n<li class=\"toc-level-3\">6.3.19 Beigene Ltd.<\/li>\n<li class=\"toc-level-3\">6.3.20 Oncternal Therapeutics<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-6\">7. \uc2dc\uc7a5 \uae30\ud68c \ubc0f \ubbf8\ub798 \uc804\ub9dd<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\uc2e0\uaddc T\uc138\ud3ec \uba74\uc5ed\uce58\ub8cc\uc81c \uc2dc\uc7a5 \ubd84\uc11d \ubcf4\uace0\uc11c (2025-2030\ub144 \uc131\uc7a5 \ub3d9\ud5a5 \ubc0f \uc804\ub9dd)<\/p>\n<p># \uc2dc\uc7a5 \uac1c\uc694 \ubc0f \uc131\uc7a5 \uc804\ub9dd<\/p>\n<p>\uc2e0\uaddc T\uc138\ud3ec \uba74\uc5ed\uce58\ub8cc\uc81c \uc2dc\uc7a5\uc740 2025\ub144 1\uc5b5 140\ub9cc \ub2ec\ub7ec \uaddc\ubaa8\uc5d0\uc11c 2030\ub144\uc5d0\ub294 5\uc5b5 6,870\ub9cc \ub2ec\ub7ec\uc5d0 \uc774\ub97c \uac83\uc73c\ub85c \uc804\ub9dd\ub418\uba70, 2025\ub144\ubd80\ud130 2030\ub144\uae4c\uc9c0 \uc5f0\ud3c9\uade0 41.5%\uc758 \uac00\ud30c\ub978 \uc131\uc7a5\ub960\uc744 \ubcf4\uc77c \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4. \uc774\ub294 \ud574\ub2f9 \ubd84\uc57c\uac00 \uc2e4\ud5d8\uc801 \uce58\ub8cc\ubc95\uc5d0\uc11c \uc0c1\uc5c5\uc801\uc73c\ub85c \ud655\uc7a5 \uac00\ub2a5\ud55c \uce58\ub8cc\ubc95\uc73c\ub85c \uc804\ud658\ub418\uace0 \uc788\uc74c\uc744 \uc2dc\uc0ac\ud569\ub2c8\ub2e4. \ud68d\uae30\uc801\uc778 \uaddc\uc81c \uc2b9\uc778, \uc790\uac00\uba74\uc5ed \uc9c8\ud658 \ubc0f \uace0\ud615\uc554 \ubd84\uc57c\ub85c\uc758 \uc784\uc0c1 \uc801\uc6a9 \ud655\ub300, \uadf8\ub9ac\uace0 \uc790\ub3d9\ud654\ub41c \uc81c\uc870 \uacf5\uc815\uc5d0 \ub300\ud55c \ud22c\uc790 \uac00\uc18d\ud654\uac00 \uc2dc\uc7a5 \uacbd\uc7c1 \uc5ed\ud559\uc744 \uc7ac\ud3b8\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. CAR-T(\ud0a4\uba54\ub77c \ud56d\uc6d0 \uc218\uc6a9\uccb4 T\uc138\ud3ec) \ud50c\ub7ab\ud3fc\uc774 \uc5ec\uc804\ud788 \uc8fc\uc694 \uc218\uc775\uc6d0 \uc5ed\ud560\uc744 \ud558\uace0 \uc788\uc9c0\ub9cc, \ud658\uc790 \ub9de\ucda4\ud615 \uc0dd\uc0b0\uc758 \ubcd1\ubaa9 \ud604\uc0c1\uc744 \ud574\uacb0\ud560 \uc218 \uc788\ub294 \ub3d9\uc885\uc720\ub798(allogeneic) \uae30\uc131\ud488(off-the-shelf) \uc811\uadfc \ubc29\uc2dd\uc774 \uc810\ucc28 \ud0c4\ub825\uc744 \ubc1b\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ubd81\ubbf8 \uc9c0\uc5ed\uc740 \uc6b0\ud638\uc801\uc778 \uc0c1\ud658 \uacbd\ub85c \ub355\ubd84\uc5d0 \uc9c0\uc18d\uc801\uc73c\ub85c \uc218\uc694\ub97c \uacac\uc778\ud558\uace0 \uc788\uc73c\uba70, \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591 \uc9c0\uc5ed\uc740 \uaddc\uc81c \uac1c\ud601\uc5d0 \ud798\uc785\uc5b4 \uac00\uc7a5 \ube60\ub978 \uc9c0\uc5ed \uc131\uc7a5\uc138\ub97c \ubcf4\uc774\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc81c\uc870 \uc790\ub3d9\ud654\ub294 \ube44\uc6a9\uacfc \uc0dd\uc0b0 \uc8fc\uae30\ub97c \ub2e8\ucd95\uc2dc\ud0a4\uae30 \uc2dc\uc791\ud558\uc5ec, \ud604\uc7ac\uc758 \uc0c1\ud658 \ub9c8\ucc30\uc774 \uc644\ud654\ub418\uba74 \uc138\ud3ec \uce58\ub8cc\uc81c\uc758 \uad11\ubc94\uc704\ud55c \ucc44\ud0dd\uc744 \uc704\ud55c \uae30\ubc18\uc744 \ub9c8\ub828\ud560 \uac83\uc73c\ub85c \uae30\ub300\ub429\ub2c8\ub2e4.<\/p>\n<p># \uc8fc\uc694 \uc2dc\uc7a5 \ud1b5\uacc4 (2024\ub144 \uae30\uc900)<\/p>\n<p>*   \uce58\ub8cc \uc720\ud615\ubcc4: CAR-T\uac00 \uc2e0\uaddc T\uc138\ud3ec \uba74\uc5ed\uce58\ub8cc\uc81c \uc2dc\uc7a5 \uc810\uc720\uc728\uc758 96.1%\ub97c \ucc28\uc9c0\ud588\uc73c\uba70, \ub3d9\uc885\uc720\ub798 \ud50c\ub7ab\ud3fc\uc740 2030\ub144\uae4c\uc9c0 41.5%\uc758 \uc5f0\ud3c9\uade0 \uc131\uc7a5\ub960\uc744 \uae30\ub85d\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4.<br \/>\n*   \uc138\ud3ec \uacf5\uae09\uc6d0\ubcc4: \uc790\uac00\uc720\ub798(autologous) \uc81c\ud488\uc774 \uc2dc\uc7a5 \uc810\uc720\uc728\uc758 93.4%\ub97c \ucc28\uc9c0\ud588\uc73c\uba70, \ub3d9\uc885\uc720\ub798 \uc81c\ud488\uc740 2030\ub144\uae4c\uc9c0 38.9%\uc758 \uc5f0\ud3c9\uade0 \uc131\uc7a5\ub960\ub85c \uc131\uc7a5\uc744 \uc8fc\ub3c4\ud560 \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4.<br \/>\n*   \uc801\uc751\uc99d\ubcc4: \ud608\uc561\uc554(hematologic malignancies)\uc774 \ub9e4\ucd9c \uc810\uc720\uc728\uc758 88.7%\ub97c \ucc28\uc9c0\ud588\uc73c\uba70, \uc790\uac00\uba74\uc5ed \uc9c8\ud658 \uc801\uc6a9\uc740 2030\ub144\uae4c\uc9c0 38.7%\uc758 \uc5f0\ud3c9\uade0 \uc131\uc7a5\ub960\uc744 \uae30\ub85d\ud560 \uac83\uc73c\ub85c \uc608\uce21\ub429\ub2c8\ub2e4.<br \/>\n*   \uc9c0\uc5ed\ubcc4: \ubd81\ubbf8\uac00 \uc2dc\uc7a5 \uaddc\ubaa8\uc758 60.2%\ub97c \ucc28\uc9c0\ud558\uba70 \uc2e0\uaddc T\uc138\ud3ec \uba74\uc5ed\uce58\ub8cc\uc81c \uc2dc\uc7a5\uc744 \uc120\ub3c4\ud588\uc73c\uba70, \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591 \uc9c0\uc5ed\uc740 2030\ub144\uae4c\uc9c0 30.5%\uc758 \uc5f0\ud3c9\uade0 \uc131\uc7a5\ub960\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p># \uc2dc\uc7a5 \ub3d9\ud5a5 \ubc0f \ud1b5\ucc30\ub825<\/p>\n<p>\uc131\uc7a5 \ub3d9\ub825 (Drivers)<\/p>\n<p>*   \uc2e0\uc18d \uc2b9\uc778 \ubc0f RMAT\/PRIME \uc9c0\uc815 \ud1b5\ud55c \uaddc\uc81c \uc9c0\uc6d0 (+8.2% CAGR \uc601\ud5a5): FDA\uc758 RMAT(\uc7ac\uc0dd\uc758\ud559 \ucca8\ub2e8\uce58\ub8cc\uc81c) \uacbd\ub85c\uc640 EMA\uc758 PRIME(\uc6b0\uc120\uc21c\uc704 \uc758\uc57d\ud488) \uc9c0\uc815\uc740 \ud45c\uc900 \uc2ec\uc0ac \uc8fc\uae30\ub97c \ub2e8\ucd95\uc2dc\ud0a4\uace0 \uc911\ubcf5 \uc784\uc0c1 \uc2dc\ud5d8\uc744 \uc904\uc5ec \ub2e4\uad6d\uc801 \ucd9c\uc2dc\ub97c \uac00\uc18d\ud654\ud569\ub2c8\ub2e4. \uc774\ub294 \uac1c\ubc1c\uc0ac\uc758 \ud604\uae08 \uc18c\uc9c4 \uae30\uac04\uc744 \uc904\uc774\uace0 \ud22c\uc790 \uc704\ud5d8\uc744 \ub0ae\ucdb0 iPSC(\uc720\ub3c4\ub9cc\ub2a5\uc904\uae30\uc138\ud3ec) \uc720\ub798 \uce58\ub8cc\uc81c\uc640 \uac19\uc740 \uc0c8\ub85c\uc6b4 \uce58\ub8cc\ubc95\uc758 \uc870\uae30 \uc2dc\uc7a5 \uc9c4\uc785\uc744 \ucd09\uc9c4\ud569\ub2c8\ub2e4.<br \/>\n*   \uc885\uc591\ud559 \ubc0f \uc790\uac00\uba74\uc5ed \ubd84\uc57c \ud6c4\uae30 \uc784\uc0c1 \ud30c\uc774\ud504\ub77c\uc778\uc758 \uae09\uc18d\ud55c \ud655\uc7a5 (+7.5% CAGR \uc601\ud5a5): 2025\ub144 \uae30\uc900 85\uac1c \uc774\uc0c1\uc758 CRISPR \uae30\ubc18 \uc784\uc0c1 \uc2dc\ud5d8\uc774 \uc9c4\ud589 \uc911\uc774\uba70, \uc774\ub294 2020\ub144 \ub300\ube44 340% \uc99d\uac00\ud55c \uc218\uce58\uc785\ub2c8\ub2e4. \uace0\ud615\uc554(\ud65c\ub9c9 \uc721\uc885\uc5d0 \ub300\ud55c Adaptimmune\uc758 TCR-T \uc2b9\uc778) \ubc0f \uc790\uac00\uba74\uc5ed \uc9c8\ud658(\uc804\uc2e0\uc131 \ud64d\ubc18\uc131 \ub8e8\ud478\uc2a4\uc5d0 \ub300\ud55c CAR-T \uc5f0\uad6c)\uc5d0\uc11c\uc758 \uc131\uacf5\uc740 \uce58\ub8cc \ubc94\uc704 \ud655\ub300\ub97c \ubcf4\uc5ec\uc90d\ub2c8\ub2e4. \uc784\uc0c1 \uc2dc\ud5d8\ub7c9 \uc99d\uac00\ub294 CMO(\uc704\ud0c1\uc0dd\uc0b0\uae30\uad00)\uc758 \uc9c0\uc5ed\ubcc4 \uc0dd\uc0b0 \ub2a5\ub825 \ud655\ub300\ub97c \uc720\ub3c4\ud558\uc5ec \ub354 \ube60\ub978 \ubb3c\ub958\ub97c \uac00\ub2a5\ud558\uac8c \ud569\ub2c8\ub2e4.<br \/>\n*   \uc720\uc804\uc790 \ud3b8\uc9d1 \ubc0f \uc138\ud3ec \uc81c\uc870 \ud50c\ub7ab\ud3fc\uc758 \ud601\uc2e0\uc744 \ud1b5\ud55c \ud6a8\ub2a5 \ubc0f \uc218\uc728 \uc99d\ub300 (+6.8% CAGR \uc601\ud5a5): Cellares\uc758 Cell Shuttle\uacfc \uac19\uc740 \uc790\ub3d9\ud654 \ud50c\ub7ab\ud3fc\uc740 \ucc98\ub9ac\ub7c9\uc744 760% \uc99d\uac00\uc2dc\ud0a4\uace0 \ube44\uc6a9\uc744 30% \uc808\uac10\ud588\uc2b5\ub2c8\ub2e4. \uc5fc\uae30 \ud3b8\uc9d1(base-editing) \uae30\uc220\uc740 \uc624\ud504\ud0c0\uac9f(off-target) \ubcc0\uc774\ub97c \uc904\uc5ec \uc548\uc804\uc131\uc744 \ub192\uc785\ub2c8\ub2e4. \ud3d0\uc1c4\ud615 \uc2dc\uc2a4\ud15c \ud558\ub4dc\uc6e8\uc5b4\ub294 \ud655\uc7a5, \ud3b8\uc9d1 \ubc0f \ud488\uc9c8 \uad00\ub9ac\ub97c \ub2e8\uc77c \uc7a5\uce58\uc5d0 \ud1b5\ud569\ud558\uc5ec \uc624\uc5fc \uc704\ud5d8\uc744 \ub0ae\ucd94\uace0 \ubc30\uce58 \uc77c\uad00\uc131\uc744 \uc720\uc9c0\ud569\ub2c8\ub2e4. \uc774\ub7ec\ud55c \ubc1c\uc804\uc740 \ubbf8\ub798 \uc218\uc694\ub97c \ucda9\uc871\uc2dc\ud0a4\uba74\uc11c \uac00\uaca9 \ud558\ub77d\uc744 \uc720\ub3c4\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4.<br \/>\n*   \uc804\ub7b5\uc801 \uc790\ubcf8 \uc720\uc785 \ubc0f \uae00\ub85c\ubc8c \ud30c\ud2b8\ub108\uc2ed\uc744 \ud1b5\ud55c \uc0c1\uc5c5\ud654 \ud655\ub300 (+5.9% CAGR \uc601\ud5a5): Roche\uc758 Poseida Therapeutics \uc778\uc218(15\uc5b5 \ub2ec\ub7ec), AstraZeneca\uc640 Cellectis\uc758 \uc81c\ud734(22\uc5b5 \ub2ec\ub7ec) \ub4f1 \uc5c5\uacc4 \uc804\ubc18\uc758 \uac70\ub798\uac00 \ud65c\ubc1c\ud569\ub2c8\ub2e4. \ubca4\ucc98 \uce90\ud53c\ud0c8\uc740 \uc790\ub3d9\ud654 \ubd84\uc57c\uc5d0 \uc801\uadf9\uc801\uc73c\ub85c \ud22c\uc790\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ube45\ud30c\ub9c8\uc640\uc758 \uc81c\ud734\ub294 \uc2e0\ud765 \ud50c\ub7ab\ud3fc\uc758 GMP(\uc6b0\uc218 \uc758\uc57d\ud488 \uc81c\uc870 \ubc0f \ud488\uc9c8 \uad00\ub9ac \uae30\uc900) \ud658\uacbd\uc73c\ub85c\uc758 \uae30\uc220 \uc774\uc804\uc744 \uac00\uc18d\ud654\ud558\uc5ec \uc0c1\uc5c5\ud654 \uc77c\uc815\uc744 \ub2e8\ucd95\uc2dc\ud0b5\ub2c8\ub2e4.<br \/>\n*   \uce58\ub8cc \ubaa9\uc801\uc758 \uc77c\ud68c\uc131 \uce58\ub8cc\uc81c\uc5d0 \ub300\ud55c \uc758\ub8cc \uc2dc\uc2a4\ud15c\uc758 \uc9c0\ubd88 \uc758\uc9c0 \uc99d\uac00 (+4.7% CAGR \uc601\ud5a5):<br \/>\n*   \uc778\uc99d\ub41c \uce58\ub8cc \uc13c\ud130\uc758 \uc9c0\ub9ac\uc801 \ud655\uc7a5\uc744 \ud1b5\ud55c \ud658\uc790 \uc811\uadfc\uc131 \uac1c\uc120 (+3.4% CAGR \uc601\ud5a5):<\/p>\n<p>\uc81c\uc57d \uc694\uc778 (Restraints)<\/p>\n<p>*   \ucd08\uace0\uac00 \ube44\uc6a9 \ubc0f \ubd88\ud655\uc2e4\ud55c \uc7a5\uae30 \uc0c1\ud658 \ud504\ub808\uc784\uc6cc\ud06c (-12.3% CAGR \uc601\ud5a5): \ud604\uc7ac \uce58\ub8cc \ube44\uc6a9\uc740 \uc8fc\uc785\ub2f9 30\ub9cc~60\ub9cc \ub2ec\ub7ec\uc5d0 \ub2ec\ud558\uba70, \uc785\uc6d0 \ubc0f \ubd80\uc791\uc6a9 \uad00\ub9ac \ube44\uc6a9\uc744 \ud3ec\ud568\ud558\uba74 \ucd1d \uce58\ub8cc \ube44\uc6a9\uc740 100\ub9cc \ub2ec\ub7ec\ub97c \ub118\uc5b4\uc124 \uc218 \uc788\uc2b5\ub2c8\ub2e4. \uc81c\uc870 \ube44\uc6a9\uc758 \uc808\ubc18\uc774 \uc778\uac74\ube44\ub85c, \uc18c\ub7c9\uc758 \uc790\uac00\uc720\ub798 \uc0dd\uc0b0\uc5d0\uc11c\ub294 \uaddc\ubaa8\uc758 \uacbd\uc81c\ub97c \ub2ec\uc131\ud558\uae30 \uc5b4\ub835\uc2b5\ub2c8\ub2e4. \uc790\ub3d9\ud654 \uc2dc\uc2a4\ud15c\uc740 \ube44\uc6a9\uc744 \uc808\uac10\ud560 \uc218 \uc788\uc9c0\ub9cc, \ucd08\uae30 \uc790\ubcf8 \ud22c\uc790\uac00 \ud544\uc694\ud569\ub2c8\ub2e4. \ubbf8\uad6d\uc758 \uba54\ub514\ucf00\uc774\ub4dc \ud504\ub85c\uadf8\ub7a8\uc740 \uc5ec\uc804\ud788 \uc8fc\ubcc4\ub85c \uc0c1\ud658\uc744 \ud611\uc0c1\ud558\uc5ec \uc81c\uc870\uc5c5\uccb4\uc758 \ud604\uae08 \uc804\ud658 \uc8fc\uae30\ub97c \uc9c0\uc5f0\uc2dc\ud0b5\ub2c8\ub2e4.<br \/>\n*   \ubcf5\uc7a1\ud558\uace0 \uc790\uc6d0 \uc9d1\uc57d\uc801\uc778 \uc81c\uc870 \ubc0f \ubb3c\ub958\ub85c \uc778\ud55c \ud655\uc7a5\uc131 \uc81c\ud55c (-8.7% CAGR \uc601\ud5a5): \uc790\uac00\uc720\ub798 \uc0dd\uc0b0\uc740 \uc5ec\ub7ec \ubc88\uc758 \uac1c\ubc29\ud615 \uc870\uc791\uc744 \ud3ec\ud568\ud558\ub294 35\ub2e8\uacc4\uc758 \ubcf5\uc7a1\ud55c \uacfc\uc815\uc744 \uac70\uce58\uba70, \ubc30\uce58 \uc2e4\ud328 \uc704\ud5d8\uc774 \uc788\uace0 &#8216;\uc815\ub9e5\uc5d0\uc11c \uc815\ub9e5\uae4c\uc9c0(vein-to-vein)&#8217; \uc18c\uc694 \uc2dc\uac04\uc774 4\uc8fc\uc5d0 \ub2ec\ud569\ub2c8\ub2e4. \uadf9\uc800\uc628 \ubcf4\uc874\ub41c \ubc31\ud608\uad6c \ubd84\ub9ac \ubb3c\uc9c8\uc758 \ucf5c\ub4dc\uccb4\uc778 \uc6b4\uc1a1\uc740 -150\u00b0C \ubcf4\uad00\uc744 \ud544\uc694\ub85c \ud558\uc5ec \uc2e0\ud765 \uacbd\uc81c\uad6d\uc5d0\uc11c\ub294 \ubb3c\ub958 \uc81c\uc57d\uc774 \ub429\ub2c8\ub2e4. GMP \uaddc\uc81c\uc758 \uc9c0\uc5ed\ubcc4 \ucc28\uc774\ub294 \ub124\ud2b8\uc6cc\ud06c \ucd5c\uc801\ud654\ub97c \ubcf5\uc7a1\ud558\uac8c \ub9cc\ub4e4\uc5b4 \uae30\uc5c5\ub4e4\uc774 \uc911\ubcf5\ub41c \uc0dd\uc0b0 \ub2a5\ub825\uc744 \uc720\uc9c0\ud558\uac8c \ud558\uc5ec \ube44\uc6a9\uc744 \uc99d\uac00\uc2dc\ud0b5\ub2c8\ub2e4.<br \/>\n*   \uc0ac\uc774\ud1a0\uce74\uc778 \ud3ed\ud48d \ubc0f \uc2e0\uacbd\ub3c5\uc131 \ub4f1 \uc548\uc804 \uad00\ub9ac \ubb38\uc81c (-6.1% CAGR \uc601\ud5a5):<br \/>\n*   \uc2e0\ud765 \uc2dc\uc7a5\uc758 \uaddc\uc81c \uc774\uc9c8\uc131 \ubc0f \ubcd1\uc6d0 \uc778\ud504\ub77c \uaca9\ucc28 (-4.2% CAGR \uc601\ud5a5):<\/p>\n<p># \uc138\uadf8\uba3c\ud2b8 \ubd84\uc11d<\/p>\n<p>\uce58\ub8cc \uc720\ud615\ubcc4: CAR-T\uc758 \uc9c0\ubc30\ub825\uacfc \uc2dc\uc7a5 \uc9c4\ud654<br \/>\n2024\ub144 \uc2e0\uaddc T\uc138\ud3ec \uba74\uc5ed\uce58\ub8cc\uc81c \uc2dc\uc7a5 \ub9e4\ucd9c\uc758 96.1%\ub97c CAR-T \ud50c\ub7ab\ud3fc\uc774 \ucc28\uc9c0\ud558\uba70 \uc9c0\ubc30\uc801\uc778 \uc704\uce58\ub97c \uc720\uc9c0\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc774\ub294 CAR-T\uc758 \ud48d\ubd80\ud55c \uc784\uc0c1 \uacbd\ud5d8, \uc0c1\uc5c5\uc801 \uc778\ud504\ub77c, \uadf8\ub9ac\uace0 \uc6b0\ud638\uc801\uc778 \uc0c1\ud658 \ucf54\ub4dc\uc5d0 \uae30\uc778\ud569\ub2c8\ub2e4. \ud604\uc7ac 7\uac1c\uc758 FDA \uc2b9\uc778 CAR-T \uc81c\ud488\uc774 \ub2e4\uc591\ud55c B\uc138\ud3ec \uc545\uc131 \uc885\uc591\uc5d0 \uc801\uc6a9\ub418\uace0 \uc788\uc73c\uba70, \uc77c\ubd80 \ud658\uc790 \ucf54\ud638\ud2b8\uc5d0\uc11c\ub294 4\ub144 \uc0dd\uc874\uc728\uc774 70% \uc774\uc0c1\uc73c\ub85c \ubcf4\uace0\ub418\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uadf8\ub7ec\ub098 \ub3d9\uc885\uc720\ub798 CAR-T \ud30c\uc774\ud504\ub77c\uc778\uc740 \uc219\uc8fc \ub300 \uc774\uc2dd\ud3b8 \ud569\ubcd1\uc99d\uc744 \ucd5c\uc18c\ud654\ud558\ub294 \uc720\uc804\uc790 \ud3b8\uc9d1 \uc548\uc804 \uc7a5\uce58\uc5d0 \ud798\uc785\uc5b4 2030\ub144\uae4c\uc9c0 41.5%\uc758 \uc5f0\ud3c9\uade0 \uc131\uc7a5\ub960\ub85c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4. \uac1c\ubc1c\uc0ac\ub4e4\uc740 \ubc94\uc6a9 \uacf5\uc5ec\uc790 \uc138\ud3ec\ub97c \ud65c\uc6a9\ud558\uc5ec \uc81c\uc870 \ub300\uae30 \uc2dc\uac04\uc744 \uc5c6\uc560\uace0 \uc788\uc73c\uba70, \uc774\ub294 \uae09\uc131 \uc9c8\ud658 \ud658\uc790\uc5d0\uac8c \uc911\uc694\ud55c \uc774\uc810\uc785\ub2c8\ub2e4. \uc804\uc774\uc131 \ud751\uc0c9\uc885\uc5d0\uc11c 31.5%\uc758 \uac1d\uad00\uc801 \ubc18\uc751\ub960\uc744 \ubcf4\uc778 lifileucel\ub85c \uc785\uc99d\ub41c \uc885\uc591 \uce68\uc724 \ub9bc\ud504\uad6c(TIL) \uce58\ub8cc\uc81c\uc758 \uc9c0\uc18d\uc801\uc778 \ubc1c\uc804\uc740 \uce58\ub8cc \uc591\uc2dd\uc758 \ub2e4\uc591\uc131\uc744 \ud655\ub300\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ud65c\ub9c9 \uc721\uc885\uc5d0\uc11c\uc758 TCR-T \uc131\uacf5\uc740 \uace0\ud615\uc554 \uce58\ub8cc\uc758 \uc7a0\uc7ac\ub825\uc744 \uac15\uc870\ud558\uba70, \uc790\uc5f0 \uc0b4\ud574(NK) \uc138\ud3ec \uc81c\ud488\uc740 \uc548\uc804\uc131 \uc774\uc810\uacfc \ud568\uaed8 \uc120\ucc9c\uc801 \uc138\ud3ec \ub3c5\uc131\uc744 \uc81c\uacf5\ud569\ub2c8\ub2e4.<\/p>\n<p>\uc138\ud3ec \uacf5\uae09\uc6d0\ubcc4: \uc790\uac00\uc720\ub798\uc758 \ub9ac\ub354\uc2ed\uacfc \ub3d9\uc885\uc720\ub798\uc758 \ub3c4\uc804<br \/>\n2024\ub144 \uc2e0\uaddc T\uc138\ud3ec \uba74\uc5ed\uce58\ub8cc\uc81c \uc2dc\uc7a5 \uc810\uc720\uc728\uc758 93.4%\ub97c \uc790\uac00\uc720\ub798 \uce58\ub8cc\uc81c\uac00 \ucc28\uc9c0\ud588\uc2b5\ub2c8\ub2e4. \uc774\ub294 \uac1c\uc778 \ub9de\ucda4\ud615 \ud56d\uc6d0 \uc778\uc2dd\uacfc \uc5ed\uc0ac\uc801\uc73c\ub85c \ub354 \uc21c\uc870\ub85c\uc6b4 \uaddc\uc81c \uacbd\ub85c \ub355\ubd84\uc785\ub2c8\ub2e4. \ud658\uc790 \ub9de\ucda4\ud615 \uc81c\ud488\uc740 \uc774\uc2dd\ud3b8\ub300\uc219\uc8fc\ubcd1(GVHD) \uc704\ud5d8\uc744 \ucd5c\uc18c\ud654\ud558\uace0 \ud608\uc561\ud559\uc801 \uc801\uc751\uc99d \uc804\ubc18\uc5d0 \uac78\uccd0 \uac15\ub825\ud55c \uc0dd\ucc29 \ud504\ub85c\ud30c\uc77c\uc744 \ubcf4\uc5ec\uc90d\ub2c8\ub2e4. \uadf8\ub7ec\ub098 &#8216;\uc815\ub9e5\uc5d0\uc11c \uc815\ub9e5\uae4c\uc9c0&#8217;\uc758 \uc8fc\uae30\ub294 20\uc77c \uc774\uc0c1 \uc18c\uc694\ub418\uba70, \ucd5c\ub300 5%\uc758 \uc81c\uc870 \uc2e4\ud328\uc728\uc740 \ube44\uc6a9\uc774 \ub9ce\uc774 \ub4dc\ub294 \uc7ac\uc81c\uc870 \ub8e8\ud504\ub97c \ubc1c\uc0dd\uc2dc\ud0b5\ub2c8\ub2e4. \ub3d9\uc885\uc720\ub798 \ud6c4\ubcf4 \ubb3c\uc9c8\uc740 38.9%\uc758 \uc5f0\ud3c9\uade0 \uc131\uc7a5\ub960\ub85c \ud655\uc7a5\ub420 \uac83\uc73c\ub85c \uc608\uc0c1\ub418\uba70, \uc989\uac01\uc801\uc778 \uc628\ub514\ub9e8\ub4dc \ud22c\uc5ec\uc640 \uaddc\ubaa8\uc758 \uacbd\uc81c\ub97c \uac00\ub2a5\ud558\uac8c \ud558\ub294 \uc911\uc559 \uc9d1\uc911\uc2dd \uc0dd\uc0b0\uc744 \uc57d\uc18d\ud569\ub2c8\ub2e4. Fate Therapeutics\uc758 iPSC \uc720\ub798 CAR-T \ub77c\uc778\uc774 \uc804\uc2e0\uc131 \ud64d\ubc18\uc131 \ub8e8\ud478\uc2a4\uc5d0 \ub300\ud574 RMAT \uc9c0\uc704\ub97c \ud655\ubcf4\ud55c \uac83\uc740 \ubc94\uc6a9 \uacf5\uc5ec\uc790 \ud50c\ub7ab\ud3fc\uc5d0 \ub300\ud55c \uaddc\uc81c \ub2f9\uad6d\uc758 \uc2e0\ub8b0\ub97c \ubcf4\uc5ec\uc90d\ub2c8\ub2e4.<\/p>\n<p>\uc801\uc751\uc99d\ubcc4: \ud608\uc561\uc554 \uae30\ubc18\uc5d0\uc11c \uc0c8\ub85c\uc6b4 \uc601\uc5ed\uc73c\ub85c \ud655\uc7a5<br \/>\n2024\ub144 \ub9e4\ucd9c\uc758 88.7%\ub97c \ud608\uc561\uc554\uc774 \ucc28\uc9c0\ud588\uc73c\uba70, \uc774\ub294 B\uc138\ud3ec \ub9bc\ud504\uc885 \ubc0f \ub2e4\ubc1c\uc131 \uace8\uc218\uc885\uc5d0\uc11c CAR-T \uce58\ub8cc\uc81c\uc758 \ud6a8\ub2a5\uc744 \uc785\uc99d\ud569\ub2c8\ub2e4. Abecma \ubc0f Carvykti\uc640 \uac19\uc740 BCMA \ud45c\uc801 \uce58\ub8cc\uc81c\ub294 \uc138 \uc790\ub9bf\uc218 \ud310\ub9e4 \uc131\uc7a5\uc744 \uae30\ub85d\ud558\uba70 \ucc28\uc138\ub300 \ud56d\uc6d0 \ud45c\uc801\uc5d0 \ub300\ud55c \uc2e0\ub8b0\ub97c \uac15\ud654\ud588\uc2b5\ub2c8\ub2e4. \ubc18\uc751 \uc9c0\uc18d\uc131\uc740 \ub192\uc740 \ucd08\uae30 \ube44\uc6a9\uc744 \uc9c0\ubd88\ud558\ub824\ub294 \uc9c0\ubd88\uc790\uc758 \uc758\uc9c0\ub97c \ub4b7\ubc1b\uce68\ud558\uba70, \ud608\uc561\uc554\uc774 \uc2e0\uaddc T\uc138\ud3ec \uba74\uc5ed\uce58\ub8cc\uc81c \uc2dc\uc7a5\uc758 \ud604\uae08 \uc5d4\uc9c4\uc784\uc744 \uacf5\uace0\ud788 \ud569\ub2c8\ub2e4. \uadf8\ub7ec\ub098 \uc790\uac00\uba74\uc5ed \uc9c8\ud658\uc740 B\uc138\ud3ec \uace0\uac08 \ud6c4 \uc7a5\uae30 \uad00\ud574\ub97c \ubcf4\uc5ec\uc8fc\ub294 \ucd08\uae30 \ub2e8\uacc4 \ub370\uc774\ud130\uc5d0 \ud798\uc785\uc5b4 2030\ub144\uae4c\uc9c0 38.7%\uc758 \uc5f0\ud3c9\uade0 \uc131\uc7a5\ub960\ub85c \uc131\uc7a5\uc744 \uc8fc\ub3c4\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4. Kyverna\uc758 KYV-101\uc740 \ub2e4\ubc1c\uc131 \uacbd\ud654\uc99d\uc5d0 \ub300\ud55c \uc911\ucd94\uc801\uc778 \uc784\uc0c1 \uc2dc\ud5d8\uc744 \uc9c4\ud589 \uc911\uc774\uba70, \ucd08\uae30 \uc804\uc2e0\uc131 \ud64d\ubc18\uc131 \ub8e8\ud478\uc2a4 \uacb0\uacfc\ub294 6\uac1c\uc6d4 \uc2dc\uc810\uc5d0\uc11c 70%\uc758 \ubb34\ubc1c\ubcd1 \uc0dd\uc874\uc728\uc744 \ubcf4\uace0\ud588\uc2b5\ub2c8\ub2e4. \uace0\ud615\uc554 \ubd84\uc57c\uc5d0\uc11c\ub294 TCR-T \ub610\ub294 \ub3d9\uc885\uc720\ub798 CAR-T \ud615\uc2dd\uc744 \uc0ac\uc6a9\ud558\uc5ec MAGE-A4, NY-ESO-1, PRAME \ud45c\uc801\uc744 \uc911\uc2ec\uc73c\ub85c \ubaa8\uba58\ud140\uc774 \uad6c\ucd95\ub418\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p># \uc9c0\uc5ed \ubd84\uc11d<\/p>\n<p>*   \ubd81\ubbf8: 2024\ub144 \uc2e0\uaddc T\uc138\ud3ec \uba74\uc5ed\uce58\ub8cc\uc81c \uc2dc\uc7a5 \uaddc\ubaa8\uc758 60.2%\ub97c \ucc28\uc9c0\ud558\uba70 \uc120\ub450\ub97c \ub2ec\ub9ac\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc774\ub294 \uac15\ub825\ud55c \uc0c1\ud658 \ud504\ub808\uc784\uc6cc\ud06c, 311\uac1c\uc758 \uc778\uc99d\ub41c \uce58\ub8cc \uc13c\ud130, \uadf8\ub9ac\uace0 FDA\uc758 \uc2e0\uc18d \uc2b9\uc778 \uacbd\ub85c \uc8fc\ub3c4 \ub355\ubd84\uc785\ub2c8\ub2e4. \uba54\ub514\ucf00\uc5b4\uc758 2025 \ud68c\uacc4\uc5f0\ub3c4 CAR-T \uc0ac\ub840\ub2f9 \uae30\ubcf8 \uc694\uc728 6.4% \uc778\uc0c1(274,413\ub2ec\ub7ec)\uc740 \ubcd1\uc6d0 \ub9c8\uc9c4\uc744 \uac1c\uc120\ud558\uc5ec \uacf5\uae09\uc790 \ucc44\ud0dd\uc744 \uac15\ud654\ud569\ub2c8\ub2e4. Gilead\ub294 2026\ub144\uae4c\uc9c0 \uc0dd\uc0b0\ub7c9\uc744 4\ubc30 \ub298\ub9b4 \uacc4\ud68d\uc774\uba70, Novartis\ub294 7\uac1c\uc758 \ub2e4\uad6d\uc801 \uacf5\uc7a5\uc744 \uc6b4\uc601\ud558\uc5ec \uacf5\uae09 \ud0c4\ub825\uc131\uc744 \ud655\ubcf4\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591: \uc911\uad6d\uc758 \uac04\uc18c\ud654\ub41c IND(\uc784\uc0c1\uc2dc\ud5d8\uacc4\ud68d) \uc808\ucc28\uc640 \uc77c\ubcf8\uc758 1,100\uc5b5 \uc5d4(7\uc5b5 4\ucc9c\ub9cc \ub2ec\ub7ec) \uaddc\ubaa8 \uc7ac\uc0dd\uc758\ub8cc \uc9c0\uc6d0\uc5d0 \ud798\uc785\uc5b4 30.5%\uc758 \uc5f0\ud3c9\uade0 \uc131\uc7a5\ub960\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud558\ub294 \uc9c0\uc5ed\uc785\ub2c8\ub2e4. \uc774 \uc9c0\uc5ed\uc740 \uc804 \uc138\uacc4 \uc138\ud3ec \uce58\ub8cc \uc784\uc0c1 \uc2dc\ud5d8\uc758 48%\ub97c \uc8fc\ucd5c\ud558\uc5ec \uc2a4\ud3f0\uc11c\uc5d0\uac8c \ube60\ub978 \ud658\uc790 \ub4f1\ub85d\uacfc \uc720\uc804\uc801 \ub2e4\uc591\uc131\uc744 \uc81c\uacf5\ud569\ub2c8\ub2e4. \ud55c\uad6d\uc758 2025\ub144 2\uc6d4 \uc7ac\uc0dd\uc758\ub8cc\ubc95\uc740 \uc2b9\uc778 \ucc44\ub110\uc744 \ud1b5\uc77c\ud558\uc5ec \ub2e4\uad6d\uc801 \uae30\uc5c5\ub4e4\uc774 \uc11c\uc6b8 \uadfc\ucc98\uc5d0 GMP \uacf5\uc7a5\uc744 \uc124\ub9bd\ud558\ub3c4\ub85d \uc720\ub3c4\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \uc720\ub7fd: EMA PRIME \uc9c0\uc815\uacfc \ub3c5\uc77c, \uc601\uad6d, \ud504\ub791\uc2a4\uc5d0 \uac78\uce5c \uc131\uc219\ud55c \uc81c\uc870 \uc0dd\ud0dc\uacc4\ub97c \uae30\ubc18\uc73c\ub85c \uafb8\uc900\ud55c \uc131\uc7a5\uc744 \ubcf4\uc774\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uad6d\uacbd \uac04 \uc784\uc0c1 \uc2dc\ud5d8 \ub124\ud2b8\uc6cc\ud06c\ub294 \uc870\ud654\ub41c \ud504\ub85c\ud1a0\ucf5c\uc758 \uc774\uc810\uc744 \ud65c\uc6a9\ud558\uc5ec 6\uac1c\uc6d4 \uc774\ub0b4\uc5d0 \ub2e4\uae30\uad00 \uc5f0\uad6c\ub97c \ud65c\uc131\ud654\ud560 \uc218 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74, \ub0a8\ubbf8: \uc81c\ud55c\ub41c \uc778\ud504\ub77c\ub85c \uc778\ud574 \ub4a4\ucc98\uc838 \uc788\uc9c0\ub9cc, \ube0c\ub77c\uc9c8\uc758 ANVISA\ub294 EMA \ud45c\uc900\uc744 \ubaa8\ub378\ub85c \ud55c \uac00\uc774\ub4dc\ub77c\uc778\uc744 \ubc1c\ud45c\ud588\uc2b5\ub2c8\ub2e4. GCC(\uac78\ud504\ud611\ub825\ud68c\uc758) \uad6d\uac00\ub4e4\uc740 \uc9c0\uc5ed \uc885\uc591\ud559 \uc0ac\ub840\ub97c \uc720\uc9c0\ud558\uae30 \uc704\ud574 \uc8fc\uc694 \uc13c\ud130\uc5d0 \uc790\uae08\uc744 \uc9c0\uc6d0\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ub192\uc740 \uc7a5\ube44 \ube44\uc6a9\uacfc \uc778\ub825 \ubd80\uc871\uc774 \uc989\uac01\uc801\uc778 \ucc44\ud0dd\uc744 \uc800\ud574\ud558\uc9c0\ub9cc, \uc7a5\uae30\uc801\uc778 \uc778\uad6c \ud1b5\uacc4\ud559\uc801 \ubcc0\ud654\ub294 \uc774 \uc9c0\uc5ed\ub4e4\uc744 \uc2e0\uaddc T\uc138\ud3ec \uba74\uc5ed\uce58\ub8cc\uc81c \uc2dc\uc7a5\uc758 \ucd08\uae30 \uae30\uc5ec\uc790\ub85c \uc790\ub9ac\ub9e4\uae40\ud558\uac8c \ud560 \uac83\uc785\ub2c8\ub2e4.<\/p>\n<p># \uacbd\uc7c1 \ud658\uacbd<\/p>\n<p>\uc2e0\uaddc T\uc138\ud3ec \uba74\uc5ed\uce58\ub8cc\uc81c \uc2dc\uc7a5\uc740 \uc911\uac04 \uc218\uc900\uc758 \uc9d1\uc911\ub3c4\ub97c \ubcf4\uc785\ub2c8\ub2e4. Novartis, Gilead\uc758 Kite Pharma, Bristol Myers Squibb(BMS)\ub294 CAR-T \uce58\ub8cc\uc81c\uc758 \uc120\ubc1c \uc8fc\uc790\ub85c\uc11c \uc2b9\uc778\uacfc \uae00\ub85c\ubc8c \uc81c\uc870 \uae30\ubc18\uc744 \ud65c\uc6a9\ud558\uc5ec \ub9e4\ucd9c\uc744 \uc9c0\ubc30\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. Novartis\ub294 2024\ub144 \ucd1d \ub9e4\ucd9c 503\uc5b5 \ub2ec\ub7ec\ub97c \uae30\ub85d\ud588\uc73c\uba70, Kymriah\uc758 \ub450 \uc790\ub9bf\uc218 \uc131\uc7a5\uc740 \uc9c0\uc18d\uc801\uc778 \uc218\uc694\ub97c \ubcf4\uc5ec\uc90d\ub2c8\ub2e4. BMS\uc758 \uc138\ud3ec \uce58\ub8cc \ud3ec\ud2b8\ud3f4\ub9ac\uc624\ub294 \uc804\ub144 \ub300\ube44 21% \uc99d\uac00\ud55c 64\uc5b5 \ub2ec\ub7ec\uc758 \ub9e4\ucd9c\uc744 \uae30\ub85d\ud588\uc73c\uba70, \uc774\ub294 \ub2e4\ubc1c\uc131 \uace8\uc218\uc885\uc5d0\uc11c Abecma\uc758 \ube60\ub978 \uce68\ud22c\ub97c \ubc18\uc601\ud569\ub2c8\ub2e4.<\/p>\n<p>\ube44\uc6a9 \uc808\uac10 \uacbd\uc7c1\uc774 \uacbd\uc7c1 \uc804\ub7b5\uc744 \ud615\uc131\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. Ori Biotech\uc758 \ud3d0\uc1c4\ud615 \uc2dc\uc2a4\ud15c IRO \ud50c\ub7ab\ud3fc\uc740 69%\uc758 \ud615\uc9c8 \ub3c4\uc785 \ud6a8\uc728\uc744 \ub2ec\uc131\ud558\uc5ec \uae30\uc874 \uac1c\ubc29\ud615 \uacf5\uc815\uc744 \ub2a5\uac00\ud558\uace0 \ud22c\uc5ec\ub7c9\ub2f9 \ub178\ub3d9\ub825 \uc694\uad6c \uc0ac\ud56d\uc744 30% \uc904\uc600\uc2b5\ub2c8\ub2e4. 9\uac1c\uc758 \ubcd1\ub82c \uc0dd\ubb3c \ubc18\uc751\uae30\ub97c \uc81c\uacf5\ud558\ub294 Cellares\uc758 Cell Shuttle\uc740 760%\uc758 \ucc98\ub9ac\ub7c9 \uc99d\uac00\ub97c \uc57d\uc18d\ud558\uba70, \uc774\ub294 \uc6b4\uc601 \uacbd\uc81c\uc131\uc744 \uae30\ubc18\uc73c\ub85c \uc81c\uc870\uc5c5\uccb4\uc758 \uc21c\uc704\ub97c \uc7ac\uc870\uc815\ud560 \uc218 \uc788\ub294 \uae30\uc220\uc785\ub2c8\ub2e4. \uae30\uc874 \uae30\uc5c5\ub4e4\uc740 \uc2dc\uc7a5 \uc810\uc720\uc728\uc744 \ubcf4\ud638\ud558\uae30 \uc704\ud574 \uc790\ub3d9\ud654 \uc804\ubb38 \uae30\uc5c5\uacfc \ud30c\ud2b8\ub108\uc2ed\uc744 \ub9fa\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>Allogene Therapeutics \ubc0f Fate Therapeutics\uc640 \uac19\uc740 \ub3d9\uc885\uc720\ub798 \ud601\uc2e0 \uae30\uc5c5\ub4e4\uc740 \ub354 \ube60\ub978 \uce58\ub8cc \uc2dc\uac04\uc744 \ubaa9\ud45c\ub85c \ud558\ub294 \ubc94\uc6a9 \uacf5\uc5ec\uc790 \uc7ac\uace0\ub97c \ud1b5\ud574 \uc790\uac00\uc720\ub798 \uae30\uc5c5\uc758 \uc9c0\uc704\ub97c \uc704\ud611\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. FT819\uc5d0 \ub300\ud55c RMAT \uc9c0\uc704\uc640 \uac19\uc740 \uaddc\uc81c \uc2b9\ub9ac\ub294 \uc774\ub7ec\ud55c \uc804\ub7b5\uc758 \uc720\ud6a8\uc131\uc744 \uc785\uc99d\ud558\uace0 \uc790\ubcf8 \uc720\uc785\uc744 \uc720\ub3c4\ud569\ub2c8\ub2e4. \ud55c\ud3b8, \ud2c8\uc0c8 \uc2dc\uc7a5 \ud50c\ub808\uc774\uc5b4\ub4e4\uc740 \ub2e4\uc911 CRISPR \ud3b8\uc9d1 \ubc0f \uc0c8\ub85c\uc6b4 \uc0ac\uc774\ud1a0\uce74\uc778 \uce74\uc138\ud2b8 \uc8fc\ubcc0\uc5d0 \ud2b9\ud5c8\ub97c \ucd9c\uc6d0\ud558\uc5ec \uc9c0\uc18d\uc131 \ud504\ub85c\ud30c\uc77c\uc744 \ucc28\ubcc4\ud654\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uae30\uc220\uc774 \ud655\uc0b0\ub428\uc5d0 \ub530\ub77c \uc2e0\uaddc T\uc138\ud3ec \uba74\uc5ed\uce58\ub8cc\uc81c \uc2dc\uc7a5\uc740 \uc81c\uc870 \ubbfc\ucca9\uc131\uacfc \ud45c\uc801 \ud655\uc7a5\uc774 \ub2e8\uc21c\ud55c \uc601\uc5c5\ub825 \uaddc\ubaa8\ubcf4\ub2e4 \uc911\uc694\ud55c \ud50c\ub7ab\ud3fc \uc911\uc2ec \uacbd\uc7c1\uc73c\ub85c \uc804\ud658\ub418\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\uc8fc\uc694 \uc2dc\uc7a5 \ucc38\uc5ec\uc790: Novartis AG, Gilead Sciences, Bristol Myers Squibb, Johnson &#038; Johnson, Allogene Therapeutics.<\/p>\n<p># \ucd5c\uadfc \uc0b0\uc5c5 \ub3d9\ud5a5<\/p>\n<p>*   2025\ub144 3\uc6d4: Capricor Therapeutics\ub294 \ub4a4\uc13c \uadfc\uc774\uc601\uc591\uc99d \uc2ec\uadfc\ubcd1\uc99d \uce58\ub8cc\uc81c deramiocel\uc5d0 \ub300\ud574 \ubbf8\uad6d FDA\uc758 \uc6b0\uc120 \uc2ec\uc0ac\ub97c \ubc1b\uc544 \uc7a0\uc7ac\uc801\uc778 \ub3d9\uae09 \ucd5c\ucd08 \uc2b9\uc778\uc744 \uc704\ud55c \uc704\uce58\ub97c \ud655\ubcf4\ud588\uc2b5\ub2c8\ub2e4.<br \/>\n*   2025\ub144 3\uc6d4: \ubbf8\uad6d FDA\ub294 \ud2b9\ubc1c\uc131 \ud669\ubc18\ubaa8\uc138\ud608\uad00\uc99d 2\ud615 \uce58\ub8cc\ub97c \uc704\ud55c \ub3d9\uc885\uc720\ub798 \ucea1\uc290\ud654 \uc548\uad6c \uc720\uc804\uc790-\uc138\ud3ec \uce58\ub8cc\uc81c ENCELTO\ub97c \uc2b9\uc778\ud558\uc5ec \uc885\uc591\ud559 \uc678\uc758 \uc138\ud3ec \uce58\ub8cc \uc591\uc2dd\uc744 \ud655\ub300\ud588\uc2b5\ub2c8\ub2e4.<br \/>\n*   2024\ub144 11\uc6d4: \ubbf8\uad6d FDA\ub294 \uc7ac\ubc1c\uc131 \ub610\ub294 \ubd88\uc751\uc131 B\uc138\ud3ec \uc804\uad6c\uccb4 \uae09\uc131 \ub9bc\ud504\ubaa8\uad6c \ubc31\ud608\ubcd1 \uce58\ub8cc\ub97c \uc704\ud55c 8\ubc88\uc9f8 CAR-T \uce58\ub8cc\uc81c\uc778 Aucatzyl\uc744 \uc2b9\uc778\ud588\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\ubcf8 \ubcf4\uace0\uc11c\ub294 T-\uc138\ud3ec\ub97c \ud65c\uc6a9\ud558\uc5ec \uc554\uacfc \uac19\uc740 \uc9c8\ubcd1\uc744 \uce58\ub8cc\ud558\ub294 \ud601\uc2e0\uc801\uc778 \uc811\uadfc \ubc29\uc2dd\uc778 \uc2e0\uaddc T-\uc138\ud3ec \uba74\uc5ed\uce58\ub8cc\uc81c \uc2dc\uc7a5\uc5d0 \ub300\ud55c \uc2ec\uce35 \ubd84\uc11d\uc744 \uc81c\uacf5\ud569\ub2c8\ub2e4. \ubcf4\uace0\uc11c\uc758 \ubc94\uc704\ub294 \uce58\ub8cc \uc720\ud615(CAR-T, TCR-T, \uc885\uc591 \uce68\uc724 \ub9bc\ud504\uad6c(TIL), T-\uc138\ud3ec \uc778\uac8c\uc774\uc800\/BiTE \ubc0f \uae30\ud0c0 \uc2e0\uaddc \uc591\uc2dd), \uc138\ud3ec \uacf5\uae09\uc6d0(\uc790\uac00\uc720\ub798 \ubc0f \ub3d9\uc885\uc720\ub798), \uc801\uc751\uc99d(\ud608\uc561\uc554, \uace0\ud615\uc554, \uc790\uac00\uba74\uc5ed\uc9c8\ud658, \ubc14\uc774\ub7ec\uc2a4 \uac10\uc5fc \ubc0f \uae30\ud0c0 \uc801\uc751\uc99d), \uadf8\ub9ac\uace0 \uc9c0\uc5ed(\ubd81\ubbf8, \uc720\ub7fd, \uc544\uc2dc\uc544-\ud0dc\ud3c9\uc591, \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74, \ub0a8\ubbf8)\ubcc4 \uc2dc\uc7a5 \uc138\ubd84\ud654\ub97c \ud3ec\ud568\ud558\uba70, \uc2dc\uc7a5 \uc608\uce21\uc740 \uac00\uce58(USD) \uae30\uc900\uc73c\ub85c \uc81c\uc2dc\ub429\ub2c8\ub2e4.<\/p>\n<p>\uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc131\uc7a5 \uc804\ub9dd\uc5d0 \ub530\ub974\uba74, \uc2e0\uaddc T-\uc138\ud3ec \uba74\uc5ed\uce58\ub8cc\uc81c \uc2dc\uc7a5\uc740 2025\ub144 1\uc5b5 140\ub9cc \ub2ec\ub7ec \uaddc\ubaa8\uc5d0\uc11c 2030\ub144\uae4c\uc9c0 5\uc5b5 6,870\ub9cc \ub2ec\ub7ec\uc5d0 \ub3c4\ub2ec\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub418\uba70, \uc5f0\ud3c9\uade0 \uc131\uc7a5\ub960(CAGR)\uc740 41.5%\uc5d0 \ub2ec\ud558\ub294 \ub192\uc740 \uc131\uc7a5\uc138\ub97c \ubcf4\uc77c \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4.<\/p>\n<p>\uc2dc\uc7a5\uc758 \uc8fc\uc694 \uc131\uc7a5 \ub3d9\ub825\uc73c\ub85c\ub294 \uc2e0\uc18d \uc2b9\uc778 \ubc0f RMAT\/PRIME \uc9c0\uc815\uacfc \uac19\uc740 \uaddc\uc81c \uc644\ud654 \uc815\ucc45, \uc885\uc591\ud559 \ubc0f \uc790\uac00\uba74\uc5ed \ubd84\uc57c\uc5d0\uc11c \ud6c4\uae30 \uc784\uc0c1 \ud30c\uc774\ud504\ub77c\uc778\uc758 \uae09\uc18d\ud55c \ud655\uc7a5, \uc720\uc804\uc790 \ud3b8\uc9d1 \ubc0f \uc138\ud3ec \uc81c\uc870 \ud50c\ub7ab\ud3fc\uc758 \uae30\uc220 \ud601\uc2e0\uc744 \ud1b5\ud55c \ud6a8\ub2a5 \ubc0f \uc218\uc728 \uc99d\ub300, \uc804\ub7b5\uc801 \uc790\ubcf8 \uc720\uc785 \ubc0f \uae00\ub85c\ubc8c \ud30c\ud2b8\ub108\uc2ed\uc744 \ud1b5\ud55c \uc0c1\uc5c5\ud654 \uac00\uc18d\ud654, \uadf8\ub9ac\uace0 1\ud68c\uc131 \uc644\uce58 \uce58\ub8cc\uc81c\uc5d0 \ub300\ud55c \uc758\ub8cc \uc2dc\uc2a4\ud15c\uc758 \uc9c0\ubd88 \uc758\uc9c0 \uc99d\uac00, \uacf5\uc778 \uce58\ub8cc \uc13c\ud130\uc758 \uc9c0\ub9ac\uc801 \ud655\uc7a5\uc744 \ud1b5\ud55c \ud658\uc790 \uc811\uadfc\uc131 \uac1c\uc120 \ub4f1\uc774 \uaf3d\ud799\ub2c8\ub2e4.<\/p>\n<p>\ubc18\uba74, \uc2dc\uc7a5 \uc131\uc7a5\uc744 \uc800\ud574\ud558\ub294 \uc694\uc778\uc73c\ub85c\ub294 \uce58\ub8cc\uc81c\uc758 \ucd08\uace0\uac00 \ube44\uc6a9\uacfc \ubd88\ud655\uc2e4\ud55c \uc7a5\uae30 \uc0c1\ud658 \ud504\ub808\uc784\uc6cc\ud06c, \ubcf5\uc7a1\ud558\uace0 \uc790\uc6d0 \uc9d1\uc57d\uc801\uc778 \uc81c\uc870 \ubc0f \ubb3c\ub958 \uacfc\uc815\uc73c\ub85c \uc778\ud55c \ud655\uc7a5\uc131 \uc81c\ud55c, \uc0ac\uc774\ud1a0\uce74\uc778 \ud3ed\ud48d \ubc0f \uc2e0\uacbd\ub3c5\uc131\uacfc \uac19\uc740 \uc548\uc804 \uad00\ub9ac \ubb38\uc81c, \uadf8\ub9ac\uace0 \uc2e0\ud765 \uc2dc\uc7a5\uc5d0\uc11c\uc758 \uaddc\uc81c \uc774\uc9c8\uc131 \ubc0f \ubcd1\uc6d0 \uc778\ud504\ub77c \uaca9\ucc28 \ub4f1\uc774 \uc9c0\uc801\ub429\ub2c8\ub2e4.<\/p>\n<p>\uc138\ubd80 \uc2dc\uc7a5 \ubd84\uc11d \uacb0\uacfc, \uce58\ub8cc \uc720\ud615\ubcc4\ub85c\ub294 CAR-T\uac00 \uc804 \uc138\uacc4 \ub9e4\ucd9c\uc758 96.1%\ub97c \ucc28\uc9c0\ud558\uba70 \uc555\ub3c4\uc801\uc778 \uc8fc\ub3c4\uad8c\uc744 \uc720\uc9c0\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc138\ud3ec \uacf5\uae09\uc6d0\ubcc4\ub85c\ub294 \uae30\uc131\ud488(off-the-shelf)\uc758 \ud3b8\ub9ac\uc131 \ub355\ubd84\uc5d0 \ub3d9\uc885\uc720\ub798(Allogeneic) \ud50c\ub7ab\ud3fc\uc774 2030\ub144\uae4c\uc9c0 38.9%\uc758 \uac00\uc7a5 \ube60\ub978 CAGR\ub85c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uce21\ub429\ub2c8\ub2e4. \uc9c0\uc5ed\ubcc4\ub85c\ub294 \uaddc\uc81c \uac1c\ud601\uacfc \uc784\uc0c1 \uc2dc\ud5d8 \ud65c\ub3d9 \uc99d\uac00\uc5d0 \ud798\uc785\uc5b4 \uc544\uc2dc\uc544-\ud0dc\ud3c9\uc591 \uc9c0\uc5ed\uc774 30.5%\uc758 CAGR\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \ud655\uc7a5\ub420 \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4.<\/p>\n<p>\uacbd\uc7c1 \ud658\uacbd \ubd84\uc11d\uc5d0\uc11c\ub294 \uc2dc\uc7a5 \uc9d1\uc911\ub3c4\uc640 \uc2dc\uc7a5 \uc810\uc720\uc728 \ubd84\uc11d\uc774 \ud3ec\ud568\ub418\uba70, Novartis AG, Gilead Sciences (Kite Pharma), Bristol Myers Squibb, Johnson &#038; Johnson (Janssen\/Legend) \ub4f1 \uc8fc\uc694 20\uac1c \uae30\uc5c5\uc758 \ud504\ub85c\ud544\uc774 \uc0c1\uc138\ud788 \ub2e4\ub8e8\uc5b4\uc9d1\ub2c8\ub2e4. \uc774\ub4e4 \uae30\uc5c5\uc758 \uae00\ub85c\ubc8c \ubc0f \uc2dc\uc7a5 \uc218\uc900 \uac1c\uc694, \ud575\uc2ec \ubd80\ubb38, \uc7ac\ubb34 \uc815\ubcf4, \uc804\ub7b5\uc801 \uc815\ubcf4, \uc2dc\uc7a5 \uc21c\uc704\/\uc810\uc720\uc728, \uc81c\ud488 \ubc0f \uc11c\ube44\uc2a4, \ucd5c\uadfc \uac1c\ubc1c \uc0ac\ud56d \ub4f1\uc774 \ud3ec\ud568\ub429\ub2c8\ub2e4.<\/p>\n<p>\uacb0\ub860\uc801\uc73c\ub85c, \uc2e0\uaddc T-\uc138\ud3ec \uba74\uc5ed\uce58\ub8cc\uc81c \uc2dc\uc7a5\uc740 \ub192\uc740 \uc131\uc7a5 \uc7a0\uc7ac\ub825\uc744 \uac00\uc9c0\uace0 \uc788\uc73c\ub098, \ube44\uc6a9 \ubc0f \uc811\uadfc\uc131, \uc81c\uc870 \ubc0f \uc548\uc804\uc131 \uad00\ub9ac \uce21\uba74\uc5d0\uc11c \ud574\uacb0\ud574\uc57c \ud560 \uacfc\uc81c \ub610\ud55c \uba85\ud655\ud569\ub2c8\ub2e4. \ubcf4\uace0\uc11c\ub294 \uc774\ub7ec\ud55c \uc2dc\uc7a5 \uae30\ud68c\uc640 \ubbf8\ub798 \uc804\ub9dd, \uadf8\ub9ac\uace0 \ubbf8\ucda9\uc871 \uc218\uc694\uc5d0 \ub300\ud55c \ud3c9\uac00\ub97c \uc81c\uacf5\ud558\uc5ec \uc774\ud574\uad00\uacc4\uc790\ub4e4\uc5d0\uac8c \uc911\uc694\ud55c \ud1b5\ucc30\ub825\uc744 \uc81c\uacf5\ud569\ub2c8\ub2e4.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-60827","post","type-post","status-publish","format-standard","hentry","category-market-reports"],"_links":{"self":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts\/60827"}],"collection":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/comments?post=60827"}],"version-history":[{"count":0,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts\/60827\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/media?parent=60827"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/categories?post=60827"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/tags?post=60827"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}